GlassScriptPhysician profile
Jose Gonzales
NPI 1144221615
$11,356.71
in general payments reported to CMS, 2019-2025
48 companies · $1,674 in 2025
The $1,674 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,675 · 2020: $918 · 2021: $1,926 · 2022: $1,919 · 2023: $1,715 · 2024: $1,530 · 2025: $1,674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,856 · Education: $62.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,856.08 |
| Education | $62.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,992.14 | 2021-2025 | |
| Novo Nordisk INC | $1,367.80 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,073.06 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $829.80 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Lilly USA, LLC | $636.04 | 2019-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $622.24 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $534.84 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $473.15 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $444.18 | 2019-2025 | Jardiance, Synjardy |
| Takeda Pharmaceuticals U.S.A., INC. | $386.44 | 2019-2024 | Trintellix |
| Pfizer INC. | $331.68 | 2019-2025 | |
| Amgen INC. | $280.26 | 2019-2024 | Repatha, Otezla, Evenity |
| Amarin Pharma, INC. | $253.02 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $179.32 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $178.77 | 2024-2025 | Voquezna |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Gonzales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.